dc.contributor.author | Rodrigues Amorim, Daniela | |
dc.contributor.author | Rivera Baltanás, Tania | |
dc.contributor.author | Vallejo Curto, María del Carmen | |
dc.contributor.author | Rodriguez Jamardo, Cynthia | |
dc.contributor.author | de las Heras, Elena | |
dc.contributor.author | Barreiro Villar, Carolina | |
dc.contributor.author | Blanco Formoso, María | |
dc.contributor.author | Fernández Palleiro, Patricia | |
dc.contributor.author | Álvarez Ariza, María | |
dc.contributor.author | López, Marta | |
dc.contributor.author | García Caballero, Alejandro | |
dc.contributor.author | Olivares, José Manuel | |
dc.contributor.author | Spuch Calvar, Carlos | |
dc.date.accessioned | 2022-10-06T12:26:13Z | |
dc.date.available | 2022-10-06T12:26:13Z | |
dc.date.issued | 2020-08-31 | |
dc.identifier.citation | Scientific Reports, 10(1): 14271 (2020) | spa |
dc.identifier.issn | 20452322 | |
dc.identifier.uri | http://hdl.handle.net/11093/3923 | |
dc.description.abstract | Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of β-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of β-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, β-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ | en |
dc.description.sponsorship | Fundação para a Ciência e a Tecnologia | Ref. SFRH/BD/135623/20 | spa |
dc.description.sponsorship | Instituto de Salud Carlos III | Ref. P16/00405 | spa |
dc.description.sponsorship | Ministerio de Sanidad, Igualdad y Política Social | Ref. 2017I054 | spa |
dc.description.sponsorship | Agencia del Conocimiento en Salud | Ref. PRIS2-17 | spa |
dc.description.sponsorship | Xunta de Galicia | Ref. IN607C-2017/02 | spa |
dc.description.sponsorship | Xunta de Galicia | Ref. IN607B 2018/17 | spa |
dc.language.iso | eng | spa |
dc.publisher | Scientific Reports | spa |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia | en |
dc.type | article | spa |
dc.rights.accessRights | openAccess | spa |
dc.identifier.doi | 10.1038/s41598-020-71060-4 | |
dc.identifier.editor | https://www.nature.com/articles/s41598-020-71060-4 | spa |
dc.publisher.departamento | Química Física | spa |
dc.publisher.departamento | Comunicación audiovisual e publicidade | spa |
dc.publisher.grupoinvestigacion | TEAM NANO TECH (Grupo de Nanotecnoloxía) | spa |
dc.subject.unesco | 3211 Psiquiatría | spa |
dc.subject.unesco | 3208 Farmacodinámica | spa |
dc.subject.unesco | 6106.07 Procesos Mentales | spa |
dc.date.updated | 2022-10-06T08:07:52Z | |
dc.computerCitation | pub_title=Scientific Reports|volume=10|journal_number=1|start_pag=14271|end_pag= | spa |